Hookipa Biotech Gmbh

Klaus Orlinger

Katherine Cohen

Thomas P Monath

Andreas Aspöck

Elizabeth Watson

Gerhard Fuhrmann

Bettina Kiefmann

Sarah Schmidt

Farshad Guirakhoo

Karen Lingnau

Michael Schwendinger

Anders Lilja

Vera Baumgartl-Strasser

Mario Aistleithner

Katharina Bayer

Elsa Mühlbacher

Ursula Berka

Manuela Kainer

Julia Hinteramskogler

Bernhard Brim

Andreas Aspock

Elsa Muhlbacher

Thomas Monath

Andreas ASPÖCK

Elsa MÜHLBACHER

Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.

CMV vaccines

Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.

HPV vaccines

The present application relates generally to genetically modified arenaviruses that are suitable vaccines against neoplastic diseases, such as cancer. The arenaviruses described herein may be suitable for vaccines and/or treatment of neoplastic diseases and/or for the use in immunotherapies. In particular, provided herein are methods and compositions for treating a neoplastic disease by administering a genetically modified arenavirus in combination with an immune checkpoint inhibitor, wherein the arenavirus has been engineered to include a nucleotide sequence encoding a tumor antigen, tumor associated antigen or antigenic fragment thereof.

Arenavirus particles as cancer vaccines

Growing community of inventors

Vienna, Austria

Klaus Orlinger